SCHEMBL776856

SCHEMBL776856

CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H](CO)COC(=O)CCCCCCCCCCCCCCC.CCOP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.72
PRKCA P17252 3/20 0.67
PRKCE Q02156 2/20 0.67
PRKCQ Q04759 2/20 0.67
PRKCD Q05655 2/20 0.67
SELP P16109 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.60
NR5A2 O00482 1/20 0.60
NR5A1 Q13285 1/20 0.60
S1PR1 P21453 1/20 0.59
ALDH1A1 P00352 1/20 0.54
ENPP2 Q13822 1/20 0.54
P2RY10 O00398 2/20 0.53
GPR34 Q9UPC5 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899991 0.95 FABP3 (0.65) FABP3PRKCAPRKCEPRKCQPRKCD
Hydrochloric Acid SCHEMBL415484 0.93 FABP3 (0.79) FABP3PRKCAPRKCEPRKCQPRKCD
Diolein SCHEMBL16100175 0.92 PRKCA (0.71) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL13695210 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL20494173 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL25403277 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL18025185 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL21713133 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL4991825 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD
SCHEMBL21641641 0.91 FABP3 (0.88) FABP3PRKCAPRKCEPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10076567-B2 MPER-liposome conjugates and uses thereof DUKE UNIVERSITY (US) 2018-09-18 US disclosed
US-20170014503-A1 MPER-LIPOSOME CONJUGATES AND USES THEREOF LOS ALAMOS NATIONAL SECURITY, LLC 2017-01-19 US disclosed
US-9402917-B2 Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions DUKE UNIVERSITY (US) 2016-08-02 US disclosed
US-20150147387-A1 METHOD OF INDUCING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS INVOLVING THE ADMINISTRATION OF MPER PEPTIDE-LIPOSOME CONJUGATES DUKE UNIVERSITY 2015-05-28 US disclosed
US-8956627-B2 Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates DUKE UNIVERSITY (US) 2015-02-17 US disclosed
US-20140322262-A1 METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS DUKE UNIVERSITY (NC) 2014-10-30 US disclosed
EP-2694533-A2 METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS Duke University (US) 2014-02-12 EP disclosed
WO-2012139097-A2 METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS DUKE UNIVERSITY (US) 2012-10-11 WO disclosed
US-20120177721-A1 FORMULATION CHILDREN'S MEDICAL CENTER CORPORATION 2012-07-12 US disclosed
US-20120128758-A1 FORMULATION FOR INDUCING BROADLY REACTIVE NEUTRALIZING ANTI-HIV ANTIBODIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-05-24 US disclosed
US-20120070488-A1 METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS DUKE UNIVERSITY (US) 2012-03-22 US disclosed
US-20100047331-A1 METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-02-25 US disclosed